PaxVax

PaxVax is a vaccine startup developing oral vaccine candidates for influenza and critical infectious diseases. PaxVax has developed a proprietary oral vaccine technology based on adenovirus. This technology eliminates delivery barriers associated with traditional injectable vaccines. To date, PaxVax has raised over $50 million from investors, including Ignition Partners and Wellcome Trust, and has received funding from the National Institutes of Health.